Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.45 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268819 | 1.00 | PKM (0.47) | PKMAKR1B1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL19905697 | 1.00 | PKM (0.47) | PKMAKR1B1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL2266416 | 1.00 | PKM (0.47) | PKMAKR1B1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL2264085 | 0.83 | PKM (0.50) | PKMAKR1B1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL2272299 | 0.81 | PGR (0.55) | PKMAKR1B1CMA1AHRPDE7A | |
| SCHEMBL25255334 | 0.79 | MEN1 (0.46) | PKMAKR1B1CMA1AHRHTR6 | |
| SCHEMBL13731904 | 0.76 | AKR1B1 (0.44) | PKMAKR1B1CMA1AHRPDE7A | |
| SCHEMBL23836087 | 0.76 | AKR1B1 (0.44) | PKMAKR1B1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL23835849 | 0.76 | AKR1B1 (0.44) | PKMAKR1B1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL5344885 | 0.74 | AHR (0.46) | PKMAKR1B1KCNQ3KCNQ2KCNQ4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2011092293-A2 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, CRH | PKM 3872/4885AKR1B1 922/4885KCNQ3 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.